FOCUS
H ealtH care spending in the US accounted for nearly 18% of gross domestic product in 2015, with 4% annual growth over [2008] [2009] [2010] [2011] [2012] [2013] , and this growth is further projected to increase to 5.8% annually (https:// www.cdc.gov/nchs/fastats/health-expenditures.htm). 31 Because the cost of health care continues to increase, there is a growing emphasis on assessing the relative economic value of medical treatment options to guide resource allocation. Furthermore, given that an estimated 60% of health care spending is linked to or impacted by physicians, it is essential that physicians are armed with high-quality scientific evidence on both the treatments' effectiveness and their associated financial cost. 4 The trend toward value-based medicine is particularly pertinent to the field of neurosurgery, because it remains one of the most expensive areas in medicine while also being the most profitable specialty for hospitals. 52, 67 Whereas economic evaluation of spine surgery has received sig-nificant attention in the literature over the last 10 years, other subspecialties of neurosurgery have been less scrutinized. 32, 46, 67 To our knowledge, this is the first systematic review of cost-effectiveness studies of cranial neurosurgery procedures.
Methods

Search Strategy and Study Selection
This study was registered at the International Prospective Register of Systematic Reviews (PROSPERO; CRD42017064708). We performed a systematic review of literature following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines, using 3 databases-PubMed, EMBASE, and the Cochrane Library-to identify all economic evaluation studies of cranial neurosurgery. 48 We used the National Health Service Economic Evaluation Database (NHS EED) search filter and MeSH terms to identify studies under the theme of economic evaluation and cranial neurosurgery (Table 1) . 17 An additional manual search was performed using references from review articles and in Google Scholar, using the same search terms as noted above.
Titles and abstracts were reviewed to identify studies published between January 1, 1995, and May 1, 2017, with a focus on comparative economic evaluation of any cranial neurosurgery procedures. Studies were excluded if they involved nonneurosurgical procedures (i.e., general surgery procedures, orthopedic procedures) or noncranial neurosurgical procedures, including spine surgery. Non-English publication, editorials, technical reports, conference abstracts, errata, book chapters, case reports, or burden-of-illness studies, and study types other than cost-effectiveness analysis or cost-utility analysis were excluded. A secondary review of full texts was done to specifically identify studies that measured health outcomes in life years (LYs), quality-adjusted life years (QALYs), or disability-adjusted life years (DALYs).
Data Extraction, Synthesis, and Analysis
For all included studies, 3 independent reviewers (W.H.A.R., M.M.H.Y., S.M.) extracted the study data using a standardized abstraction form developed a priori. Data fields included the following: author; country; currency year (specific fiscal year used in determining cost value in the study); year of publication; journal of publication; study design (cost-effectiveness analysis, cost-utility analysis); economic evaluation model (Markov model, decision tree model); perspective (health care system, health care payer, society); data source (literature, singlestudy estimates, hospital database, national database such as Medicare/Medicaid); comparators (treatments being compared); patient population (specific neurological condition of interest); time horizon (duration of time that the cost and health outcome of interest were being evaluated); discount rate (analysis to adjust for changes in cost and health outcome associated with passage of time); health outcome measure (LYs, QALYs, DALYs); sensitivity analysis (1-way, multiway, probabilistic analysis); uncertainty parameters (variables incorporated into the sensitivity analysis); study results (estimated cost and health outcome of interest, incremental cost-effectiveness ratio [ICER]); and funding source (public, industry support). Each study was categorized by neurosurgical subspecialty based on diagnosis and intervention.
For clarity in study terminology, we defined a costeffectiveness analysis as a study in which the health outcome in single natural units such as LYs was used, with results reported as monetary unit per LY saved. 24 We defined a cost-utility analysis as a study in which multidimensional health outcomes such as QALYs or DALYs were used, with results reported as monetary unit per QALY or DALY gained. 24 Cost-effectiveness ratio refers to cost per health outcome (i.e., LY or QALY) for a specific intervention in question. The term ICER refers to the ratio of difference in the cost of the 2 interventions over the difference in health outcomes.
Based on the previously published report by Zygourakis and Kahn, which highlighted significant heterogeneity of economic evaluation studies in neurosurgery, including study methodology (i.e., simple cost comparison versus full economic evaluation using cost-utility analysis) and primary outcomes measures (QALYs, LYs, DALYs), data analysis was performed in a descriptive manner. 67 For each study, the reported cost-effectiveness ratio or ICER was converted from their initial value to 2016 US dollars by using the Campbell and Cochrane Economics Methods Group (CCEMG) and the Evidence for Policy and Practice Information and Coordinating Centre (EPPI-Centre) (i.e., CCEMG-EPPI-Centre) cost converter. 55 This online tool was developed based on published research from the CCEMG-EPPI-Centre. 55 It allows standardized comparison of cost variables in multiple studies by adjusting for differences in currencies and currency year. For studies that failed to report the currency year, the year of publication was used as the surrogate currency year.
The converted cost-effectiveness ratio or ICER was then assessed against a commonly used willingness to pay (WTP) threshold of US$50,000 per health outcome (i.e., QALYs or LYs). 20 The WTP threshold represents a theoretical maximum cost of an intervention that is deemed acceptable by the health care payer in order to achieve a specified health outcome such as QALYs or LYs. 20 The specific intervention being studied was deemed dominant over the alternative treatment option if it met the following criteria: 1) less costly and 2) led to improved health outcome. For studies included in our systematic review that reported sensitivity analysis, we extracted variables that were found to be influential in the reported cost-effectiveness ratio (i.e., cost of procedure, discount rate).
Three independent reviewers performed quality assessment of the studies by using the Drummond checklist for assessing economic evaluations. 9 This validated questionnaire consists of 10 items that address key requirements of economic studies in health care, with scores of 8 deemed as high quality. Discrepancies in scores were resolved through discussion between the reviewers.
Results
Search Results and Study Characteristics
In total, 3485 citations were reviewed, of which 53 studies met the inclusion criteria (Fig. 1) ; 64% (34 studies) of these were published in the last 5 years (Fig. 2) . 1-3, 5-8, 10-16, 19,21,22,25-30,33-43,45,47,49-51,53,54, 56-66,68 The most common subspecialty focuses of these cost-effectiveness studies were cerebrovascular neurosurgery (32%), followed by neurooncology (26%) and functional neurosurgery (24%) (Fig. 3) . The preponderance of studies originated in the US (47%), followed by the United Kingdom (UK; 9%) and the Netherlands (9%) (Fig. 4) . Twenty-seven studies (51%) did not specify the source of funding. Of the studies that included funding source, 30% were supported by a public 
FIG. 3.
Bar graph showing distribution of economic evaluation studies based on subspecialty of neurosurgery. Studies are organized based on the reported cost-effectiveness ratio against the WTP threshold of US$50,000 per health outcome (i.e., QALY, LY). The specific intervention being studied was deemed dominant over the alternative treatment option if it met the following criteria: 1) less costly and 2) led to improved health outcome. If the cost-effectiveness ratio of the intervention in question was less than US$50,000 per health outcome, it was categorized as met. If the cost-effectiveness ratio of the intervention in question was more than US$50,000 per health outcome, it was categorized as unmet. N/A = not applicable. 
Study Findings and Study Quality
Detailed summaries of study results and methodology are included in Tables 2 and 3 . Twenty-eight (53%) studies found a specific surgical treatment to be cost-effective by using a WTP threshold of US$50,000 per health outcome (i.e., QALYs or LYs) (Fig. 3 ). In addition, there were 11 (21%) studies that found the specific surgical option to be dominant (both cost saving and having superior outcome). Treatments found to be dominant included endovascular thrombectomy for acute ischemic stroke compared to standard medical care; transsphenoidal surgery compared to medical treatment for prolactinoma; intraoperative mapping for low-grade glioma versus standard resection; carotid endarterectomy (CEA) compared to medical therapy for carotid stenosis; endoscopic pituitary tumor resection compared to microscopic tumor resection; and stereotactic radiosurgery compared to open surgery for metastatic brain tumors. Eight studies (15%; 3 neurooncology, 2 cerebrovascular, 2 functional, 1 epilepsy) incorporated indirect cost (i.e., loss of potential income due to illness or treatment morbidity, caregiver's time) as part of their economic evaluation.
The majority of the studies (87%) performed a sensitivity analysis to address uncertainties in the data used for their economic analysis, with the most common method being 1-way deterministic sensitivity analysis, followed by probabilistic sensitivity analysis (Table 4) . Thirty-eight of 53 studies (72%) reported using 1-way deterministic sensitivity analysis, which considers a wide range of values for a specific variable within the model (e.g., cost of treatment, patient age, complication rate, discount rate) to assess the effect of individual variables on the overall cost-effectiveness ratio. Twenty-four of 53 studies (45%) reported using probabilistic sensitivity analysis, which determines the probability of the intervention being cost-effective at certain WTP thresholds by randomly varying every input datum. The most common variables tested in sensitivity models were cost (58%), effectiveness of the treatment in question (43%), age (30%), and discount rate (26%).
Of the studies included in our review, 43 (81%) were judged to be high quality (score > 8) on the basis of the Drummond checklist (range 5-10). The most frequent reason for lower score was failure to address the following requirements: 1) adjusting cost and health outcome for differential timing (23%); 2) providing comprehensive descriptions of the competing treatment options (20%); and 3) performing sensitivity analysis for uncertainty parameters in the economic model (14%).
Discussion
To our knowledge, this is the first systematic review to examine and summarize the current body of evidence on the cost-effectiveness of cranial neurosurgery. We identified 53 studies that evaluated a specific operative neurosurgical intervention against an alternative treatment in a cost-effectiveness context. These articles addressed topics in all subspecialties of neurosurgery, including pediatrics, functional, epilepsy, cerebrovascular, general neurosurgery, and neurooncology; however, cerebrovascular, neurooncology, and functional neurosurgery were the most prevalent. The findings of our review reflect a growing emphasis on incorporating economic value within neurosurgical decision making and continuing the growth of economic evaluation research in neurosurgery. A previous nonsystematic review by Zygourakis and Kahn examined 26 economic evaluation studies of neurosurgery published before 2014; however, they found that many were not true cost-effectiveness studies. 67 In addition, a number of those studies focused on nonoperative practices such as the use of diagnostic imaging for brain injury. 23 In contrast, we found 30 studies focused specifically on operative neurosurgical care that were published between 2013 and 2017. More importantly, 74% of the 53 included studies found that the treatment evaluated was dominant or cost-effective at a WTP threshold of US$50,000 per health outcome (i.e., QALYs, LYs).
Eleven studies (21%) found that a treatment was economically dominant compared to the alternative considered. Three of these studies highlighted the cost-effectiveness benefit of endovascular thrombectomy for acute ischemic stroke, 2, 40, 56 and reflect the recent advances from multiple clinical trials, such as the ESCAPE (Endovascular Treatment for Small Core and Proximal Occlusion Ischemic Stroke) trial, which show a significant increase in the number of functionally independent patients after endovascular thrombectomy. 18 A similar long-term economic benefit of reduced stroke-related disability was reported by Nussbaum et al., who found CEA dominant over medical management in patients with symptomatic carotid stenosis. 45 The impact of improved long-term patient outcome in cost-effectiveness analysis was also demonstrated in surgical management for medically intractable epilepsy, awake craniotomy for low-grade glioma resection, and pituitary tumor resection. 3, 25, 41, 53 In these studies, higher direct costs often related to cost of surgery were compensated by long-term benefits and lower follow-up costs. 3, 25, 41, 53 In contrast, 3 studies evaluating the cost-effectiveness of metastatic brain tumor treatment, for which life expectancy remains more limited, found that options with lower procedural cost and lower postoperative morbidity were dominant. These included stereotactic radiosurgery and intraoperative brachytherapy. [63] [64] [65] Compared with the findings of Zygourakis and Kahn in their earlier review of the literature, certain subspecialties of neurosurgery, particularly cerebrovascular and neurooncology, have contributed a significant number of cost-effectiveness studies (31/53 studies in our review), particularly within the last 5 years. 67 However, other subspecialties (epilepsy, neuro-critical care, and pediatrics) remain poorly represented in the health economics literature, with only a few published studies. We view this as a call-to-arms and an opportunity to conduct health economic studies examining treatments within these particular subspecialties.
Limitations of the Study
The literature we identified was unfortunately too het- The cost-effectiveness ratio of the intervention in question (i.e., cost per health outcome) was compared against the WTP threshold of US$50,000/QALY or LY. * Study did not report a cost-effectiveness ratio or ICER, and therefore we were unable to determine whether intervention met the WTP threshold.
» CONTINUED FROM PAGE 6 2-way sensitivity analysis, probabilistic sensitivity analysis Utility decrements, age of simulated patients, cost of adding thrombectomy to standard care, long-term mortality, lifelong time horizon, discount rate, long-term stroke cost Major changes to all uncertainty parameters did not change ICER to cross the threshold.
At the WTP threshold of US$10,000/QALY, thrombectomy was cost-effective in 100% of cases.
Bowen et al., 2012 1-way sensitivity analysis Time horizon, discount rate, alternate utility source, assuming treatment effect for children referred to treatment center but who did not have surgery Changes to uncertainty parameters did not change conclusion of surgery dominating. Dams et al., 2013 1-way sensitivity analysis Starting age, discount rate, time until battery exchange, costs for battery exchange, cost for surgery, cost of adverse events, changes in drug cost, DBS-related mortality, improvement in motor complications, utility improvement, duration of utility improvement, periop utility reduction, shorter time horizons Model was most sensitive to treatment effect of DBS, effect of time until battery exchange, and discount rate. The cost-effectiveness threshold of €32,000/QALY was not reached in any single parameter.
de Kinderen et al., 2015
Probabilistic sensitivity analysis, 1-way sensitivity analysis Efficacy of treatment, utility values, costs At 12 mos, standard care had 100% probability of cost-effectiveness at the threshold of €20,000/QALY. However, at 5 yrs VNS had the highest probability (51%) of being costeffective at the threshold of €80,000/QALY gained, followed by standard medical care (36%) & KD (14%). 
Esteves et al., 2015
Probabilistic sensitivity analysis, 1-way sensitivity analysis Transition probabilities, costs of each health state, utility values, discount rates ICER remained <€14,000/QALY gained, €9000/LY gained in all uncertainty states. Probability of 5-ALA cost-effectiveness below the threshold of €20,000 was 99.6% for LYs, & 96% for QALY. Most influential variables were proportion of complete resection in the 5-ALA cohort & probability of death in patient groups.
Fallah et al., 2016 1-way sensitivity analysis Assumptions: full medical adherence; no adverse events; no major complications or death; 1st-line AEDs are Keppra & valproic acid, 3rd is carbamazepine, 4th is clobazam. Uncertainty parameters: cost of medications, probability of 3rd AED resulting in seizure freedom, utility of seizurefree state, utility of <50% improvement in seizures At the threshold of US$100,000/QALY gained, only the treatment option of adding the 3rd AED remained cost-effective in the sensitivity analysis. The most influential variables for ICER were health utility value of refractory seizures & the probability of having seizure freedom from the 3rd AED.
Gaetani et al., 1998
Not done Probabilistic sensitivity analysis, 1-way sensitivity analysis Health utility, probability parameters, cost No impact on conclusion at the threshold of US$30,000/QALY gained. Thrombectomy had 100% probability of being cost-effective at the WTP threshold of US$33,000/ QALY.
Garside et al., 2007
Probabilistic sensitivity analysis, 1-way sensitivity analysis Median overall survival benefit w/ treatment, median PFS benefit w/ treatment, QOL (utility) for stable disease, QOL (utility) for progressive disease, cost of treatment Most influential variables were median overall survival, median PFS, QOL utility, & cost of treatment. Carmustine wafer was not under the WTP threshold of £30,000/QALY gained in 89% of cases, and in 15% of cases the carmustine arm was dominated. Similarly, temozolomide did not meet the WTP threshold in 77% of cases. To be below the threshold, the median survival benefit needed to be 22 wks, up from 11 wks.
Garton et al., 2002 1-way sensitivity analysis Posthospitalization recovery, costs, discount rates, different rates of ETV success No impact on conclusion.
Greving et al., 2009
Probabilistic sensitivity analysis, 1-way sensitivity analysis Utility of awareness of an untreated aneurysm, development of de novo & recurrent aneurysms, clipping-& coilingrelated complications, outcome of SAH, mortality Results were sensitive to utility awareness of aneurysm & treatment-related disability.
Increasing surgical risk of death or moderate to severe disability for 70-yr-old patients resulted in increased cost-effectiveness ratio beyond the WTP threshold of €20,000/ QALY gained. Presence of vascular disease reduced the cost-effectiveness of treatment from €19,818/QALY to €22,298/QALY in 50-yr-old men, w/ a rupture rate of 0.3%/yr. Probabilistic sensitivity analysis, 1-way sensitivity analysis Tumor progression, cost, probability of subtotal resection, use of Gliadel wafer No impact on conclusion at the threshold of US$50,000/QALY gained.
Vuong et al., 2013
Probabilistic sensitivity analysis Cost, effectiveness of treatment 92% of cases showed that SRS was cheaper, & 59% of cases showed that SRS was dominant over resection.
Vuong et al., 2012
Probabilistic sensitivity analysis Cost, effectiveness of treatment 34% of cases showed that SRS was dominant over resection. erogeneous for formal meta-analysis methodology. Specifically, the economic modeling, the source of cost and health outcome data, and the sensitivity analysis often differed widely. With the establishment of the Consolidated Health Economic Evaluation Reporting Standards (CHEERS), future methodology should be more standardized. 24 To address such variability, our review protocol was developed with stringent inclusion criteria that led to the exclusion of many studies that were partial economic evaluations, such as cost comparison studies. In addition, the determination of cost-effectiveness and WTP threshold is influenced by multiple factors and varies by country and health care payer system (i.e., public health care vs private insurance). 44 The WTP threshold used in this review may not be applicable to all readers, and should be interpreted in the context of their own health care systems. The WTP threshold remains highly variable between studies, with some US-based studies applying the WTP threshold up to US$150,000/QALY based on the proposal from the WHO of 3 times the gross domestic product per capita. 20 For this review, the threshold of US$50,000 per health outcome (QALYs, LYs) was used, given the heterogeneity of the study locations and their associated variability in gross domestic product. Finally, given the high cost of neurosurgical disorders and their treatment options, there may be a potential publication bias, especially for studies supported by industry funding; perhaps studies that show lack of cost-effectiveness may be not submitted for publication.
Conclusions
There is growing body of cost-effectiveness studies in cranial neurosurgery, especially within the last 5 years. Whereas there are numerous procedures, such as endovascular thrombectomy, that have been conclusively proven to be cost-effective for acute ischemic stroke, there remain promising interventions in our current practice that have yet to meet cost-effectiveness thresholds. This systematic review hopefully highlights the importance of high-quality cost-effectiveness research in neurosurgery, and would urge future clinical trials to incorporate cost-effectiveness into their study design as well as the usual establishment of clinical efficacy.
